Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
INACTIVE COMPANY
 
My Lists

Xtent  (Stock symbol: XTNT )

125 Constitution Drive
Menlo Park, CA 94025
USA
650.475.9400
Website Company Summary Management Team
Team

Management: Randolph E Campbell (CTO)
Outside board: Allan R Will (Split Rock Partners) Michael L Eagle (Eli Lilly manufacturing) Edward W Unkart (SurgRx CFO) Patrick Latterell (Venrock Associates)Michael Carusi (Advanced Technology Ventures)Robert E Flaherty (Athena Diagnostics President/CEO/Chairman)Arthur T Taylor (Kyphon sr. executive) Christopher M Smith (Cochlear Americas President)Hank A Plain (Xtent Chairman)
Company

Business description: XTENT, Inc. develops customizable drug-eluting stent (DES) systems for the treatment of coronary artery disease. XTENT's customizable DES systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.
Capital

Rounds: 4
Recent fundings: May 2006   Mar 2005
Capital raised: 75.0M
Last Round: 30.0M
Ownership: Public   Ipo Filing
Stock Symbol: XTNT

Last Tweets


 

Last Mentions


Overview
Record updated: May 2009
Sector: Medical
Year Founded: 2002
Rounds: 4
Recent fundings: May 2006   Mar 2005
Capital raised: 75.0M
Last Round: 30.0M
Ownership: Public   Ipo Filing
Stock Symbol: XTNT